4 Former FDAers Join Parexel

Parexel says it has appointed four former FDA executives to its regulatory consulting group. Joining the team that helps client companies understand and work within current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays are Kurt Borson (CDER, specializing in viral safety of biopharmaceuticals and clearance during manufacturing, with expertise in chemistry, manufacturing, and controls review and inspections), Changting Haudenschild (over 12 years of experience in the CBER Office of Tissue and Advanced Therapies), Mohammad (Mo) Heidaran (CBER, recognized expert in development of cell and gene therapies), and Mwango Kashoki (over 16 years of drug review, development, and regulatory experience at FDA with cross-disciplinary expertise in all phases of drug development from preclinical development through marketing application and post-approval assessments).